首页 | 本学科首页   官方微博 | 高级检索  
检索        

2,6-二甲基-4-(2-氯苯基)-1,4-二氢-3,5-吡啶二羧酸二甲酯对大鼠野百合碱性肺动脉高压的防治作用
引用本文:李志超,张福琴,赵德化,梅其炳,孙本韬.2,6-二甲基-4-(2-氯苯基)-1,4-二氢-3,5-吡啶二羧酸二甲酯对大鼠野百合碱性肺动脉高压的防治作用[J].中国药理学与毒理学杂志,1997,11(3):194-198.
作者姓名:李志超  张福琴  赵德化  梅其炳  孙本韬
作者单位:第四军医大学药理学教研室室
摘    要:用野百合碱(MCT)复制大鼠慢性肺动脉高压(PH)病理模型,探讨钙拮抗剂2,6-二甲基-4-(2-氯苯基)-1,4-二氢-3,5-吡啶二羧酸二甲酯(DCDDP)对PH的防治作用. DCDDP 5, 50, 500 μg·kg-1 ip, 每日1次, 连续28 d; MCT 60 mg· kg-1在第1次给DCDDP后30 min sc.观察肺血流动力学指标变化,血浆和肺匀浆中内皮素样免疫反应物(ir-ET), 一氧化氮(NO)含量,超氧化物歧化酶(SOD)活性和丙二醛(MDA)含量的改变. 三种不同剂量的DCDDP分别使平均肺动脉压从4.5±0.9 kPa(MCT组)降至3.2±0.2, 3.5±0.6和3.8±0.9 kPa, 肺血管阻力从118±17 kPa·min-1·L-1(MCT组)降至65±16, 68±18和76±18 kPa·min-1·L-1(P<0.01), 提示在本实验剂量范围内, 中, 低剂量DCDDP防治效果似较好. DCDDP不影响MCT性PH时血浆和肺匀浆中ir-ET的改变, 但可显著升高肺匀浆中NO的含量和SOD活性, 使肺匀浆中MDA含量降至正常, 这可能是其降低肺动脉压的机理之一.

关 键 词:野百合碱  钙通道阻滞剂  2  6-二甲基-4-(2-氯苯基)-1  4-二氢-3  5-吡啶二羧酸二甲酯  内皮素类  一氧化氮  肺动脉  高血压
收稿时间:1996-3-18

Effect of dimethyl 4-(2-chlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate on the chronic pulmonary hypertension induced by monocrotaline in rats
LI Zhi-Chao, ZHANG Fu-Qin, ZHAO De-Hua, MEI Qi-Bing, SUN Ben-Tao.Effect of dimethyl 4-(2-chlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate on the chronic pulmonary hypertension induced by monocrotaline in rats[J].Chinese Journal of Pharmacology and Toxicology,1997,11(3):194-198.
Authors:LI Zhi-Chao  ZHANG Fu-Qin  ZHAO De-Hua  MEI Qi-Bing  SUN Ben-Tao
Institution:LI Zhi-Chao, ZHANG Fu-Qin1, ZHAO De-Hua, MEI Qi-Bing, SUN Ben-Tao2
Abstract:The effect of dimethyl 4-(2-chlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5- pyridinedicarboxylate (DCDDP, 5, 50, 500 μg·kg-1 ip, once a day for 28 d), a dihydropyridine calcium antagonist, on the chronic pulmonary hypertension (PH) induced by monocrotaline (MCT, 60 mg·kg-1 sc, 30 min after the first injection of DCDDP) in Sprague-Dawley rats was investigated.The parameters of pulmonary hemodynamics were monitored. The contents of endothelin-like immunoreactivity (ir-ET) and nitric oxide (NO), superoxide dismutase (SOD) activity and malondialdehyde (MDA) concentration in plasma and pulmonary homogenate were measured. The pulmonary artery pressure was droped from 4.5±0.9 kPa (MCT group) to 3.2±0.2, 3.5±0.6 and 3.8±0.9 kPa by these three doses of DCDDP, respectively; and the pulmonary resistance was decreased from 118±17 kPa·min-1·L-1 (MCT group) to 65±16, 68±18 and 76±18 kPa·min-1·L-1 respectively 28 d after injection of MCT, suggesting that the middle and low doses of DCDDP may be more effective than the high dose. DCDDP had no influence on ir-ET levels in plasma and pulmonary homogenate, but inhibited the decrease in the content of NO and the activity of SOD and prevented the elevation of the content of MDA in pulmonary homogenate by MCT. It is concluded that the mechanism of DCDDP for lowering pulmonary artery pressure may be related to inhibit the production of free radical and increase in the content of NO in lungs.
Keywords:monocrotaline  calcium channel blockers  dimethyl 4-(2-chlorophenyl)-1  4-dihydro-2  6-dimethyl-3  5-pyridinedicarboxylate  endothelins  nitric oxide  pulmonary artery  hypertension
本文献已被 维普 等数据库收录!
点击此处可从《中国药理学与毒理学杂志》浏览原始摘要信息
点击此处可从《中国药理学与毒理学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号